MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2016.11.023

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2016

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.

Okuma Yusuke, Hosomi Yukio, Nakahara Yoshiro, Watanabe Kageaki, Sagawa Yukiko, Homma Sadamu

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Programmed cell death-ligand 1 (PD-L1) expressed in tumor tissues is a key molecule for immune suppression, given its role in immune checkpoints. The significance and implication of soluble PD-L1 (sPD-L1) in the blood of lung cancer patients remain unknown.

PATIENTS AND

METHODS

Blood samples were prospectively collected from patients with advanced lung cancer, and the plasma sPD-L1 concentrations were measured by enzyme-linked immunosorbent assay. The correlations of the plasma sPD-L1 levels with clinico-pathological status, laboratory data, and survival of the patients were analyzed.

RESULTS

Ninety-six patients with advanced lung cancer were analyzed, including 73 with adenocarcinoma, 12 with squamous cell carcinoma, and seven with small-cell lung cancer. Sixty-five were naïve to chemotherapy, and 20 had received two or more lines of chemotherapy. The mean plasma sPD-L1 concentration of all the patients was 6.95±2.90ng/ml (range 2.30-20.0ng/ml), and this value is significantly increased compared with that previously reported for normal subjects. No correlation of the plasma sPD-L1 level with histological subtypes, adenocarcinoma genetic status, smoking history, clinical stage or laboratory data was found. However, overall survival was significantly reduced in patients with high (≥7.32ng/ml) compared with low (<7.32ng/ml) plasma sPD-L1 levels (13.0 vs. 20.4 months, p=0.037). Multivariate analysis revealed that high sPD-L1 levels were significantly related to poor prognosis (hazard ratio 1.99, p=0.041).

CONCLUSION

High plasma sPD-L1 levels were associated with poor prognosis in patients with advanced lung cancer, possibly associated with suppression of anti-tumor immunity. Clinical trial register and their clinical registration number: UMIN%000014760.

Для цитирования: Okuma Yusuke, Hosomi Yukio, Nakahara Yoshiro, Watanabe Kageaki, Sagawa Yukiko, Homma Sadamu. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.. Lung cancer (Amsterdam, Netherlands). 2016. DOI: 10.1016/j.lungcan.2016.11.023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.